Total Long Term Debt (Quarterly) Chart

View Total Long Term Debt (Quarterly) for SVRA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Total Long Term Debt (Quarterly) Chart
Start Trial

Historical Total Long Term Debt (Quarterly) Data

View and export this data back to 2001. Start Trial.
Date Value
June 30, 2026 30.11M
March 31, 2026 30.07M
December 31, 2025 29.91M
September 30, 2025 29.78M
June 30, 2025 29.65M
March 31, 2025 29.52M
December 31, 2024 26.71M
September 30, 2024 26.55M
June 30, 2024 26.48M
March 31, 2024 26.42M
December 31, 2023 26.60M
September 30, 2023 26.28M
June 30, 2023 26.21M
March 31, 2023 26.14M
December 31, 2022 26.13M
September 30, 2022 26.01M
June 30, 2022 25.94M
March 31, 2022 25.81M
December 31, 2021 25.77M
September 30, 2021 25.52M
June 30, 2021 25.38M
March 31, 2021 25.24M
December 31, 2020 25.19M
September 30, 2020 25.08M
June 30, 2020 24.90M
Date Value
March 31, 2020 24.93M
December 31, 2019 23.41M
September 30, 2019 25.26M
June 30, 2019 25.12M
March 31, 2019 24.68M
December 31, 2018 24.57M
September 30, 2018 15.42M
June 30, 2018 15.32M
March 31, 2018 15.20M
December 31, 2017 15.34M
September 30, 2017 15.24M
June 30, 2017 15.60M
March 31, 2017 3.502M
December 31, 2016 4.469M
September 30, 2016 14.23M
June 30, 2016 14.88M
March 31, 2016 14.84M
December 31, 2015 14.62M
September 30, 2015 14.47M
June 30, 2015 0.025M
March 31, 2015 0.027M
December 31, 2014 0.00
September 30, 2014 0.00
June 30, 2014 0.00
March 31, 2014 0.00

Total Long Term Debt Definition

Represents a company's total debt maturing for more than 12 months of the reporting period.

Read full definition.

Total Long Term Debt (Quarterly) Range, Past 5 Years

View Total Long Term Debt (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Total Long Term Debt (Quarterly) Benchmarks

View Total Long Term Debt (Quarterly) Benchmarks
Start Trial
Gilead Sciences, Inc. 26.25B
Insmed, Inc. 741.01M
United Therapeutics Corp. 0.00
Vertex Pharmaceuticals, Inc. 1.978B
SELLAS Life Sciences Group, Inc. 0.157M